Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo

BACKGROUND: Uterine sarcomas are very rare malignancies with no approved chemotherapy protocols. Histone deacetylase (HDAC) inhibitors belong to the most promising groups of compounds for molecular targeting therapy. Here, we described the antitumor effects of suberoylanilide hydroxamic acid (SAHA;...

Descripción completa

Detalles Bibliográficos
Autores principales: Hrzenjak, Andelko, Moinfar, Farid, Kremser, Marie-Luise, Strohmeier, Bettina, Petru, Edgar, Zatloukal, Kurt, Denk, Helmut
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843655/
https://www.ncbi.nlm.nih.gov/pubmed/20202195
http://dx.doi.org/10.1186/1476-4598-9-49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843655/
https://www.ncbi.nlm.nih.gov/pubmed/20202195
http://dx.doi.org/10.1186/1476-4598-9-49

Ejemplares similares